Directorate Change

Directorate Changes

Dublin, London | 17 December 2021

Uniphar plc (the "Company") wishes to announce that Ger Penny will resign from the Board with effect from 17 December 2021. Ger joined the Board as a representative of the Sisk Family on the acquisition of Sisk Healthcare Group in 2018 and resigns in line with the appointment rights granted in connection with that acquisition.

The Company also wishes to announce that Padraic Dempsey, Executive Director, will resign from the Board with effect from 17 December 2021. Padraic has served on the Board for a four-year term and will continue in his role as Chief Commercial Officer of the Group.

Maurice Pratt, Chairman of Uniphar plc, commented:

"On behalf of the Board, I would like to take this opportunity to thank Ger for the support and commitment he has shown to the Board over the last three years. Ger's experience and insights have been a great support to the Board and we wish him every success with his future endeavours.

The Directors and I would also like to thank Padraic for his valuable contributions to the Board over the past four years and we look forward to his continuing success in his executive role.

Since IPO, the Board has been focused on transitioning Board composition to meet the requirements of the UK Corporate Governance Code. The resignations announced today will mean a majority of our Board members will be considered independent, with the number of Executive Directors on the Board reducing from three to two, further enhancing the balance between Executive and Non-Executive representation on the Board."

Having regard to the current size and composition of the Board, the Board is not currently considering any new appointments to the Board at this time.

--- ENDS ---

For further details contact:

About Uniphar plc 

Headquartered in Dublin, Ireland, Uniphar is an international diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology manufacturers across three divisions - Commercial & Clinical, Product Access and Supply Chain & Retail. With a workforce of more than 3,200, the Group is active in Ireland, the UK, the Benelux, the Nordics, Germany and the US.

The Company's vision is to improve patient access to pharmaco-medical products and treatments by enhancing connectivity between manufacturers and healthcare stakeholders. Uniphar represents a strong combination of scale, growth and profitability.

Commercial & Clinical

In Commercial & Clinical the Group provides sales, marketing & distribution solutions to multinational pharmaceutical and medical device manufacturers on an outsourced basis. Active in Ireland, the UK, Benelux, the Nordics, Germany and the US, the Group is growing with its clients to provide pan-European solutions. Uniphar has built a fully integrated multi-channel solution that is supported by our highly experienced and clinically trained teams leveraging our digital technology and insights which allows us to deliver consistently exceptional outcomes for our clients.

Product Access

In Product Access the Group is growing two distinct service offerings: 1) "On Demand Access", which are pharmacy led solutions for sourcing and supplying unlicensed medicines to meet the needs of both retail and hospital pharmacists; and 2) "Exclusive Access", which are manufacturer led solutions for controlling the release of speciality medicines for specifically approved patient populations in agreed markets. The Group currently delivers product access solutions on a global basis.

Supply Chain & Retail

Uniphar is an established market leader in Ireland with over a 50% market share in the wholesale/hospital market, supported by a network of c.360 owned, franchised and symbol group pharmacies. The business supports the diverse customer base through the provision of strong service levels coupled with innovative commercial initiatives. Supply Chain & Retail is an Irish only business for the Group, although the manufacturer relationships and infrastructure are utilised for the benefit of the growth divisions, Commercial & Clinical and Product Access.